US20030077636A1 - Use of particles which have signal-emitting characteristics and at least one group with an affinity for maked nucleic acids - Google Patents
Use of particles which have signal-emitting characteristics and at least one group with an affinity for maked nucleic acids Download PDFInfo
- Publication number
- US20030077636A1 US20030077636A1 US10/239,424 US23942402A US2003077636A1 US 20030077636 A1 US20030077636 A1 US 20030077636A1 US 23942402 A US23942402 A US 23942402A US 2003077636 A1 US2003077636 A1 US 2003077636A1
- Authority
- US
- United States
- Prior art keywords
- nucleic acids
- affinity
- particles
- signal
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 35
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 35
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 35
- 239000002245 particle Substances 0.000 title claims abstract description 22
- 238000001514 detection method Methods 0.000 claims abstract description 5
- 239000002502 liposome Substances 0.000 claims description 33
- 239000000693 micelle Substances 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 230000005670 electromagnetic radiation Effects 0.000 claims description 2
- 238000004020 luminiscence type Methods 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 7
- 238000003491 array Methods 0.000 description 7
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 7
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 101100437484 Arabidopsis thaliana BGLU18 gene Proteins 0.000 description 2
- 101000908859 Arabidopsis thaliana Peptidyl-prolyl cis-trans isomerase CYP18-4 Proteins 0.000 description 2
- 101100342633 Bos taurus LLGL1 gene Proteins 0.000 description 2
- 101000921797 Caenorhabditis elegans Peptidyl-prolyl cis-trans isomerase 1 Proteins 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 101000921923 Glycine max Peptidyl-prolyl cis-trans isomerase 1 Proteins 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101100065855 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EXG1 gene Proteins 0.000 description 2
- 101100058298 Saccharomycopsis fibuligera BGL1 gene Proteins 0.000 description 2
- 239000007976 Tris-NaCl-Tween buffer Substances 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 101150100570 bglA gene Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VEQCRWBNBHJDSA-UHFFFAOYSA-N 6-amino-2-[2-[(2-iodoacetyl)amino]ethyl]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1N(CCNC(=O)CI)C(=O)C2=CC(S(O)(=O)=O)=CC3=C2C1=CC(S(O)(=O)=O)=C3N VEQCRWBNBHJDSA-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 102100021921 ATP synthase subunit a Human genes 0.000 description 1
- 102000000546 Apoferritins Human genes 0.000 description 1
- 108010002084 Apoferritins Proteins 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 241000965476 Darksidea beta Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000753741 Homo sapiens ATP synthase subunit a Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- HBTBNXFVJYRYGI-UHFFFAOYSA-M hexadecane-1-sulfinate Chemical compound CCCCCCCCCCCCCCCCS([O-])=O HBTBNXFVJYRYGI-UHFFFAOYSA-M 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- BRJCLSQFZSHLRL-UHFFFAOYSA-N oregon green 488 Chemical compound OC(=O)C1=CC(C(=O)O)=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 BRJCLSQFZSHLRL-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
Definitions
- the invention pertains to a support which enables to bind two or more differently labeled nucleic acids which have been hybridized independently from each other with nucleic acids immobilized on a surface and render them measurable using the different signal-emitting molecules incorporated into the support or provided thereon.
- Microarrays solid supports having nucleic acids immobilized thereon at different addressable positions
- the nucleic acids to be analyzed are modified such that they are afterwards identifiable and quantifiable (radioactivity, chemiluminescence, fluorescence, etc.).
- the modification may be either a molecule which can release a signal by itself (direct labeling) or a molecule which is recognized by a second molecule which in its turn is labeled (indirect labeling).
- a problem with the use of microarrays excluding a sensitive detection is the sensitivity with which the nucleic acids to be analyzed on said supports can be recognized and limited starting amounts of nucleic acid mixtures to be analyzed.
- the object of the invention is to avoid the above-mentioned drawbacks and to ensure a more precise quantification of nucleic acids.
- the addressed object is achieved by a use of particles selected from the group consisting of liposomes and/or micelles with signal-emitting characteristics and at least one group with an affinity for labeled nucleic acids for the detection of labeled nucleic acids hybridized with a nucleic acid immobilized on a surface.
- nucleic acids bear different labels. This enables, e.g., a differentiation between healthy and diseased tissue.
- the particles preferably have a particle size from 20 to 4000 nm, preferably from 200 to 400 nm.
- the particles and the preparation thereof are described in Scheffold A, Miltenyi S, Radbruch A, Magnetofluorescent liposomes for increased sensitivity of immunofluorescence. Immunotechnology 1995; 1(2): 127-37.
- the signal-emitting property is produced in particular by electromagnetic radiation, in particular fluorescence, radioactivity, luminiscence, phosphorescence, electromagnetic resonance.
- the affinity group is preferably an antibody or an antibody fragment.
- the affinity group may be directed against any type of low-molecular haptens such as, e.g., Alexa Fluor 488; amino-3-deoxydigoxigenin hemisuccinamide; biotin; BODIPY, Cascade Blue; Cy2; Cy3; Cy5; Danisyl; DNP (dinitrophenol); DIG (digoxigenin); Alexa Fluor 488; 5(6)-SFX; fluorescein; Lucifer yellow iodoacetamide; Marina Blue; Oregon Green 488; 5(6)-TAMRA; PE (phycoerythrin); Rhodamine Red; Texas Red.
- the nucleic acids have to be labeled with the appropriate haptens.
- Another object of the invention are supports having a surface on which nucleic acids hybridized with labeled nucleic acids are immobilized, where particles having signal-emitting properties and at least one group with an affinity for the labeled nucleic acids, accordingly the first affinity group, are bonded to the labeled nucleic acids.
- the particles for the supports of the invention designated for the highly sensitive immunofluorescence detection of hybridized nucleic acids preferably consist of magnetofluorescent liposomes containing several thousand fluorescing molecules and colloidal magnetic particles.
- the liposomes preferably consist of from 40 to 50 mol %, in particular 45 mol % of phosphatidylcholine, from 5 to 15 mol %, in particular 10 mol % of phosphatidylglycerol, from 2 to 10 mol %, in particular 5 mol % of phosphatidylethanolamine, and from 35 to 45 mol %, in particular 40 mol % of cholesterol.
- the liposomes When using water-soluble fluorophores (for example carboxyfluorescein), as a function of the solubility and the fluorescence behavior of the respective fluorophor the liposomes contain a 1 to 100 mM solution of the fluorescent dye which can be obtained by immersing the liposomes into a suitably concentrated fluorophor solution and a fluorophor diffusion into the liposomes.
- water-soluble fluorophores for example carboxyfluorescein
- the liposomes When using water-insoluble fluorophores, the liposomes contain the respective fluorophore in a molar ratio of from 1:100 to 1:1000 as a function of the solubility and the fluorescence behavior of the respective fluorophore.
- the fluorophore-containing liposomes are obtained during the liposome preparation as a function of the solubility and the fluorescence behavior of the fluorophor by adding the respective fluorophore in a molar ratio of from 1:100 to 1:1000, based on the number of mols of the lipids, to the lipid mixture.
- the liposomes contain superparamagnetic microparticles having diameters from 50 to 100 nm. Said particles are obtained by immersing the liposomes into a solution of a superparamagnetic microparticle with an absorption at 450 nm (optical density, OD 450 ) of 500.
- liposomes particles having a pseudofluid, diphase surface
- an affinity group is completely mobile on the liposome surface. This is of essential significance for the affinity or avidity (total bond strength between two molecules or particles which is influenced by several bond regions) of the particles since:
- the density of the applied affinity groups has to be selected very precisely since with the density being too high a mutual repulsion and hindrance is to be expected whereas with a too low loading density the probability of a bond to the target molecule is strongly reduced.
- the bond strength between rigid, spherical particles (microspheres) having diameters from 20 to 4000 nm and a relatively rigid tube having a diameter of about 2 nm (double-stranded DNA) is substantially determined by only one affinity group.
- the bond strength between fluid, spherical particles (liposomes and micelles) having diameters from 20 to 4000 nm and a relatively rigid tube having a diameter of about 2 nm (double-stranded DNA) is determined with the greatest probability by more than one affinity group.
- an antigen (target molecule) is bonded by one of both bonding sites of an antibody in a reversible bimolecular reaction.
- affinity constant K 10 5 to 10 11 L/mol.
- the simple bimolecular reaction may only be applied in the reaction of an antigen having an epitope and homogeneous antibodies.
- both bonding sites of an antibody or two connected antibodies e.g., IgM or the liposomes provided with antibodies described here
- the reaction no longer proceeds in a bimolecular manner necessitating complicated equations to be applied on the kinetics of the immune complex formation.
- both antibody bonding sites can react, e.g., the second bonding site bonds to the epitope much faster than the first one (entropic effect) since the antigen molecule is already very close to the antibody resulting in an increase of the apparent affinity (avidity) by a factor of at least 10 4 .
- the increased affinity results in an increased and more specific bonding which explains the higher sensitivity and specificity of liposomes, i.e. particles having a diphase, fluid surface, to other spheric particles.
- Antibodies e.g., anti DNP, anti DIG etc.
- RNAs to be tested were transcribed into the corresponding cDNA by a conventional reverse transcriptase (RT) reaction.
- RT reverse transcriptase
- derivatized nucleotides such as DNP-dCTP, DIG-CTP, etc., which are incorporated into the formed cDNA, are added.
- different cDNAs may be labeled in a different way in independent reactions.
- said whole cDNAs labeled in a different manner e.g., of healthy and diseased tissue, are applied to a microarray.
- the derivatized and hybridized cDNAs can be recognized using antibodies directed against them and conjugated with the liposomes and identified and quantified by measuring the different fluorescences. Hence, avoiding enzymatic amplification several thousand fluorescent molecules can be used for a correspondingly high sensitivity of the analysis in one step.
- cDNA fragments having a length of about 300 bp were generated with incorporating biotin dUTP and digoxigenin dUTP, resp., by PCR (“EC20 biotin” and “EC20 digoxigenin”, resp.), dropped twice on a coated glass slide (300 pg) and covalently bonded (see PCT/EP 99/04014).
- Each spot on these “EC20Bio 13 EC20Dig arrays” contained a mixture of both cDNA fragments in the ratios EC20:EC20 digoxigenin of 1000:1; 200:1; 40:1; 8:1; 1:1; 1:8; 1:40; 1:200, 1:1000.
- the dyed arrays were washed with shaking with TNT buffer for 20 min and with 0.06 ⁇ SSC for 2 min.
- the arrays were analyzed in a laser scanner (ScanArray 3000, General Scanning, Inc.) and the signal intensities were calculated (Imagene 2.0, Biodiscovery, Inc.), see FIG. 1 and FIG. 2.
- the green color represents bonded anti-Dig-Cy5 liposomes
- the red color represents anti biotin-Cy3 liposomes.
- Example 2 This experiment intended to establish whether the coloration by means of liposomes results in a signal increase as compared to the conventional direct incorporation of fluorescence labeled nucleotides.
- cDNA arrays with 18 different cDNAs were prepared with each cDNA being applied 8 times in total (four identical quandrants with 2 spots each).
- the applied cDNAs are summarized in table 1.
- the cDNA sequence in the respective quadrants is from the bottom of the right hand side to the top of the left hand side such that, e.g., cDNA no. 1 “EC7” can be found in the bottom right hand corner of the respective quadrant.
- RNA was extracted from murine spleen and murine liver. From this mRNA was isolated.
- FIG. 4 summarizes the signal quotients of the single arrays in a bar graph.
- the signal quotients for both methods are comparable except that with the standard method the yellow bars (initial amount of 0.01 ⁇ g) are not present for some genes since the absolute signal intensity of the basic signals is too low.
- Table 2 again summarizes the signal quotients in tabular form.
- the number of detectable genes is illustrated here. Those genes resulting in signal intensities in at least one of both fluorescence canals being at least two times greater than the corresponding signal intensity of the mean value of the negative controls (herring semen DNA and salt) are termed as “detectable genes”.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
- The subject matter of the present invention are the use according to
claim 1 and the support according toclaim 8. - The invention pertains to a support which enables to bind two or more differently labeled nucleic acids which have been hybridized independently from each other with nucleic acids immobilized on a surface and render them measurable using the different signal-emitting molecules incorporated into the support or provided thereon.
- Microarrays (solid supports having nucleic acids immobilized thereon at different addressable positions) are increasingly used for the parallel identification and the preparation of transcription profiles of polynucleic acids. Here, for hybridization the nucleic acids to be analyzed are modified such that they are afterwards identifiable and quantifiable (radioactivity, chemiluminescence, fluorescence, etc.). The modification may be either a molecule which can release a signal by itself (direct labeling) or a molecule which is recognized by a second molecule which in its turn is labeled (indirect labeling). A problem with the use of microarrays excluding a sensitive detection is the sensitivity with which the nucleic acids to be analyzed on said supports can be recognized and limited starting amounts of nucleic acid mixtures to be analyzed.
- According to the state of the art there are two possibilities to solve this problem. Firstly, one tries to amplify the available nucleic acid in different ways before hybridizing it with the microarray (T7 in vitro transcription (Eberwine et al.) or PCR, to mention only two methods). Secondly, one tries to the recognize the already hybridized and chemically modified nucleic acids using indirect labeling and direct labeling in combination therewith and to create strong signals by a secondary reaction in combination with the recognized position, e.g., by enzymatic reactions (keywords sandwich, tyramine, horseradish peroxidase, etc.). The drawbacks of this approach are that the used enzymatic methods often result in a non-linear amplification, i.e., the amount of the existing different nucleic acids is amplified in a different manner. However, since the amount of nucleic acid is to be determined by microarray analysis, the non-uniform amplification questions the complete analysis. Furthermore, both enzymatic and non-enzymatic amplification reactions are often multistage reactions and very complex.
- The object of the invention is to avoid the above-mentioned drawbacks and to ensure a more precise quantification of nucleic acids.
- According to the invention, the addressed object is achieved by a use of particles selected from the group consisting of liposomes and/or micelles with signal-emitting characteristics and at least one group with an affinity for labeled nucleic acids for the detection of labeled nucleic acids hybridized with a nucleic acid immobilized on a surface.
- In a favorable embodiment of the use of the invention the nucleic acids bear different labels. This enables, e.g., a differentiation between healthy and diseased tissue.
- The particles preferably have a particle size from 20 to 4000 nm, preferably from 200 to 400 nm. The particles and the preparation thereof are described in Scheffold A, Miltenyi S, Radbruch A, Magnetofluorescent liposomes for increased sensitivity of immunofluorescence. Immunotechnology 1995; 1(2): 127-37.
- The signal-emitting property is produced in particular by electromagnetic radiation, in particular fluorescence, radioactivity, luminiscence, phosphorescence, electromagnetic resonance.
- The affinity group is preferably an antibody or an antibody fragment. The affinity group may be directed against any type of low-molecular haptens such as, e.g., Alexa Fluor 488; amino-3-deoxydigoxigenin hemisuccinamide; biotin; BODIPY, Cascade Blue; Cy2; Cy3; Cy5; Danisyl; DNP (dinitrophenol); DIG (digoxigenin); Alexa Fluor 488; 5(6)-SFX; fluorescein; Lucifer yellow iodoacetamide; Marina Blue; Oregon Green 488; 5(6)-TAMRA; PE (phycoerythrin); Rhodamine Red; Texas Red. The nucleic acids have to be labeled with the appropriate haptens.
- Another object of the invention are supports having a surface on which nucleic acids hybridized with labeled nucleic acids are immobilized, where particles having signal-emitting properties and at least one group with an affinity for the labeled nucleic acids, accordingly the first affinity group, are bonded to the labeled nucleic acids.
- The particles for the supports of the invention designated for the highly sensitive immunofluorescence detection of hybridized nucleic acids preferably consist of magnetofluorescent liposomes containing several thousand fluorescing molecules and colloidal magnetic particles.
- The liposomes preferably consist of from 40 to 50 mol %, in particular 45 mol % of phosphatidylcholine, from 5 to 15 mol %, in particular 10 mol % of phosphatidylglycerol, from 2 to 10 mol %, in particular 5 mol % of phosphatidylethanolamine, and from 35 to 45 mol %, in particular 40 mol % of cholesterol.
- When using water-soluble fluorophores (for example carboxyfluorescein), as a function of the solubility and the fluorescence behavior of the respective fluorophor the liposomes contain a 1 to 100 mM solution of the fluorescent dye which can be obtained by immersing the liposomes into a suitably concentrated fluorophor solution and a fluorophor diffusion into the liposomes.
- When using water-insoluble fluorophores, the liposomes contain the respective fluorophore in a molar ratio of from 1:100 to 1:1000 as a function of the solubility and the fluorescence behavior of the respective fluorophore. The fluorophore-containing liposomes are obtained during the liposome preparation as a function of the solubility and the fluorescence behavior of the fluorophor by adding the respective fluorophore in a molar ratio of from 1:100 to 1:1000, based on the number of mols of the lipids, to the lipid mixture.
- The liposomes contain superparamagnetic microparticles having diameters from 50 to 100 nm. Said particles are obtained by immersing the liposomes into a solution of a superparamagnetic microparticle with an absorption at 450 nm (optical density, OD 450) of 500.
- A distinct difference between liposomes (particles having a pseudofluid, diphase surface) and all other microparticles is that due to fluid properties an affinity group is completely mobile on the liposome surface. This is of essential significance for the affinity or avidity (total bond strength between two molecules or particles which is influenced by several bond regions) of the particles since:
- A) for theoretical, sterical and production-engineering reasons only a finite number of affinity groups can be provided on the surface of a particle;
- B) the density of the applied affinity groups has to be selected very precisely since with the density being too high a mutual repulsion and hindrance is to be expected whereas with a too low loading density the probability of a bond to the target molecule is strongly reduced.
- Thus, for sterical reasons the bond strength between rigid, spherical particles (microspheres) having diameters from 20 to 4000 nm and a relatively rigid tube having a diameter of about 2 nm (double-stranded DNA) is substantially determined by only one affinity group. However, the bond strength between fluid, spherical particles (liposomes and micelles) having diameters from 20 to 4000 nm and a relatively rigid tube having a diameter of about 2 nm (double-stranded DNA) is determined with the greatest probability by more than one affinity group. This may be explained as follows: after the bonding of a target molecule by a first affinity group is effected, additional affinity groups of the same liposome can migrate to a adjacent target molecule and effect a second bonding due to the constant lateral diffusion (about 10 −6 to 10−7 m/s) which is perfectly well-known for lipid bilayers.
- In first approximation, an antigen (target molecule) is bonded by one of both bonding sites of an antibody in a reversible bimolecular reaction. For most antibodies, the affinity constant K=10 5 to 1011 L/mol. The simple bimolecular reaction may only be applied in the reaction of an antigen having an epitope and homogeneous antibodies. If two identical epitopes exist on the antigen in a distance such that both bonding sites of an antibody or two connected antibodies (e.g., IgM or the liposomes provided with antibodies described here) react with the same or two adjacent, connected antigen molecules (labeled, double-stranded DNA), the reaction no longer proceeds in a bimolecular manner necessitating complicated equations to be applied on the kinetics of the immune complex formation. If both antibody bonding sites can react, e.g., the second bonding site bonds to the epitope much faster than the first one (entropic effect) since the antigen molecule is already very close to the antibody resulting in an increase of the apparent affinity (avidity) by a factor of at least 104.
- The increased affinity (avidity) results in an increased and more specific bonding which explains the higher sensitivity and specificity of liposomes, i.e. particles having a diphase, fluid surface, to other spheric particles.
- Antibodies, e.g., anti DNP, anti DIG etc., were conjugated to the amino groups of phosphatidyl ethanolamine existing in liposomes using succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate by thiol groups which may be exposed by reagents reducing S-S groups. Typical reaction conditions were adjusted with dithiothreitol.
- The RNAs to be tested were transcribed into the corresponding cDNA by a conventional reverse transcriptase (RT) reaction. Here, derivatized nucleotides such as DNP-dCTP, DIG-CTP, etc., which are incorporated into the formed cDNA, are added. Using nucleotides derivatized in a different manner, different cDNAs may be labeled in a different way in independent reactions. For hybridization said whole cDNAs labeled in a different manner, e.g., of healthy and diseased tissue, are applied to a microarray. After hybridization, the derivatized and hybridized cDNAs can be recognized using antibodies directed against them and conjugated with the liposomes and identified and quantified by measuring the different fluorescences. Hence, avoiding enzymatic amplification several thousand fluorescent molecules can be used for a correspondingly high sensitivity of the analysis in one step.
- The invention will be illustrated in more detail by the following examples.
- cDNA fragments having a length of about 300 bp were generated with incorporating biotin dUTP and digoxigenin dUTP, resp., by PCR (“EC20 biotin” and “EC20 digoxigenin”, resp.), dropped twice on a coated glass slide (300 pg) and covalently bonded (see PCT/EP 99/04014). Each spot on these “EC20Bio 13 EC20Dig arrays” contained a mixture of both cDNA fragments in the ratios EC20:EC20 digoxigenin of 1000:1; 200:1; 40:1; 8:1; 1:1; 1:8; 1:40; 1:200, 1:1000.
- In addition, two negative controls were dropped on: 1) spotting buffer 2) herring semen DNA. The arrays were washed in TNT buffer at room temperature for 15 min, blocked with TNB buffer at room temperature for 30 min and subsequently dyed with Cy3 and Cy5 labeled liposomes (antiBio-Cy3 and antiDig-Cy5 liposomes, resp.) or with Cy3 labeled streptavidin (Strept Cy3) at room temperature with shaking (150 rpm) in a total volume of 50 μl. For this, the liposomes were washed before with the 10-fold PBS volume and centrifuged with 13,000 rpm at 4° C. for 20 min.
- Subsequently, the dyed arrays were washed with shaking with TNT buffer for 20 min and with 0.06×SSC for 2 min. The arrays were analyzed in a laser scanner (ScanArray 3000, General Scanning, Inc.) and the signal intensities were calculated (Imagene 2.0, Biodiscovery, Inc.), see FIG. 1 and FIG. 2. In the combining figure (overlay) the green color represents bonded anti-Dig-Cy5 liposomes, whereas the red color represents anti biotin-Cy3 liposomes. It can be seen that a) the coloration of cDNA fragments is specific, b) the mixing ratios of the applied cDNA fragments are detectable and c) the signal intensity of the antiBio Cy3 liposomes is greater than that if Strep Cy3.
- Example 2) This experiment intended to establish whether the coloration by means of liposomes results in a signal increase as compared to the conventional direct incorporation of fluorescence labeled nucleotides.
- For this, cDNA arrays with 18 different cDNAs (300 pg) were prepared with each cDNA being applied 8 times in total (four identical quandrants with 2 spots each). The applied cDNAs are summarized in table 1. The cDNA sequence in the respective quadrants is from the bottom of the right hand side to the top of the left hand side such that, e.g., cDNA no. 1 “EC7” can be found in the bottom right hand corner of the respective quadrant. For the test RNA was extracted from murine spleen and murine liver. From this mRNA was isolated. 1 μg, 0.1 μg and 0.01 μg, resp., of mRNA were transcribed into cDNA in a reverse transcription with incorporating a) fluorescence labeled nucleotides (Cy3-dCTP for spleen and Cy5-dCTP for liver, resp.) and b) biotinylated (spleen) and digoxigenated (liver) dUTP. Each of the conventionally labeled Cy3 and Cy5 cDNAs were hybridized together on an array. FIG. 3 reveals that the signal intensity decreases with a decrease of the initial amount such that at an initial amount of 0.01 μg signals are rarely identifiable. The samples labeled with biotin and digoxigenin, resp., were also hybridized together on arrays and subsequently labeled with anti-Bio-Cy3 and antiDig-Cy5 liposomes, resp., as described in example 1. Here, it can be recognized that the signal intensity also decreases with a decrease of the initial amount. However, also at 0.01 μg all signals are identifiable. This shows that the liposome labeling is much more sensitive than the conventional direct labeling.
- FIG. 4 summarizes the signal quotients of the single arrays in a bar graph. Here, it can be recognized that the signal quotients for both methods are comparable except that with the standard method the yellow bars (initial amount of 0.01 μg) are not present for some genes since the absolute signal intensity of the basic signals is too low. Table 2 again summarizes the signal quotients in tabular form. In addition, the number of detectable genes is illustrated here. Those genes resulting in signal intensities in at least one of both fluorescence canals being at least two times greater than the corresponding signal intensity of the mean value of the negative controls (herring semen DNA and salt) are termed as “detectable genes”. Again, this demonstrates that the liposome labeling is more sensitive than the conventional direct labeling.
TABLE 1 No. Gene Name 1 Ec7 2 Salt 3 Salmsperm DNA 4 GAPDH 5 HPRT 6 Ec17 7 GAD D45 8 beta Tubulin 9 Actin; alpha 10 Ubiquitin 11 Cyclophilin 112 BGL1 Beta-globin 13 Ec20 14 FERHA ferritin heavy chain 15 AT Pase 616 Bcl2 17 p53 18 Ec21 -
TABLE 2 1 μg mRNA 1 μg RNA starting mat starting mat Name Liposome Standard Liposome Standard ACTIN, ALPHA −1.9 −1.3 −4.2 −1.7 ATP6 ATPASE 64.2 6.3 1.0 1.5 BCL2 1.0 1.0 1.0 n.d. BETA TUBULIN −3.0 −2.6 −3.3 n.d. BGL1 BETA-GLOBIN −39.3 −39.0 −27.1 12.1 CYCLOPHILIN 11.5 1.0 1.3 1.0 FERHA FERRITIN 1.0 1.0 1.0 1.3 GAD D45 1.0 1.0 1.0 n.d. GAP DH 1.0 1.9 1.6 n.d. HPRT 1.5 1.0 −2.8 n.d. P53 1.6 −1.1 −1.6 −4.0 UBIQUITIN −1.3 1.0 −1.9 1.0 Detectable genes 12 12 12 7 (max. 12)
Claims (9)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10016115 | 2000-03-31 | ||
| DE10016115.4 | 2000-03-31 | ||
| EP00113549 | 2000-06-27 | ||
| EP00113549.0 | 2000-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030077636A1 true US20030077636A1 (en) | 2003-04-24 |
Family
ID=26005127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/239,424 Abandoned US20030077636A1 (en) | 2000-03-31 | 2001-03-31 | Use of particles which have signal-emitting characteristics and at least one group with an affinity for maked nucleic acids |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030077636A1 (en) |
| EP (1) | EP1268858A1 (en) |
| JP (1) | JP2003528625A (en) |
| AU (1) | AU2001256244A1 (en) |
| WO (1) | WO2001073117A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020084623A3 (en) * | 2018-10-24 | 2020-07-02 | Apa- Advanced Technologies Ltd. | Fusogenic liposomes for selective imaging of tumor cells |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841156B1 (en) * | 2002-06-19 | 2004-09-10 | Bio Merieux | NOVEL FLUORESCENT MAGNETIC PARTICLES, AS WELL AS CONJUGATES OF SUCH PARTICLES, AND DIAGNOSTIC, THERAPEUTIC OR PROPHYLACTIC COMPOSITIONS CONTAINING THEM |
| WO2005066401A1 (en) | 2004-01-01 | 2005-07-21 | Dsm Ip Assets B.V. | Process for making high-performance polyethylene multifilament yarn |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US5200313A (en) * | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
| US5702888A (en) * | 1988-01-12 | 1997-12-30 | Boehringer Mannheim Gmbh | Process for the detection of nucleic acids |
| US5763176A (en) * | 1993-07-12 | 1998-06-09 | Slater; James Howard | Methods and devices for marking a solid and subsequently detecting the markings |
| US5837194A (en) * | 1993-04-23 | 1998-11-17 | Potter; Colin G. | Apparatus for measuring chemiluminescence of multiple samples on a continuous matrix |
| US6383749B2 (en) * | 1999-12-02 | 2002-05-07 | Clontech Laboratories, Inc. | Methods of labeling nucleic acids for use in array based hybridization assays |
| US6506895B2 (en) * | 1997-08-15 | 2003-01-14 | Surmodics, Inc. | Photoactivatable nucleic acids |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612356B4 (en) * | 1996-03-28 | 2007-04-26 | Clondiag Chip Technologies Gmbh | Optical detection of hybridization signals |
| US6632526B1 (en) * | 1997-10-14 | 2003-10-14 | Luminex Corporation | Precision fluorescently dyed particles and methods of making and using same |
| AU1926899A (en) * | 1997-12-19 | 1999-07-12 | Affymetrix, Inc. | Exploiting genomics in the search for new drugs |
| US6203989B1 (en) * | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
-
2001
- 2001-03-31 JP JP2001570831A patent/JP2003528625A/en active Pending
- 2001-03-31 AU AU2001256244A patent/AU2001256244A1/en not_active Abandoned
- 2001-03-31 US US10/239,424 patent/US20030077636A1/en not_active Abandoned
- 2001-03-31 WO PCT/EP2001/003702 patent/WO2001073117A1/en not_active Ceased
- 2001-03-31 EP EP01929486A patent/EP1268858A1/en not_active Withdrawn
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5200313A (en) * | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
| US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US5702888A (en) * | 1988-01-12 | 1997-12-30 | Boehringer Mannheim Gmbh | Process for the detection of nucleic acids |
| US5837194A (en) * | 1993-04-23 | 1998-11-17 | Potter; Colin G. | Apparatus for measuring chemiluminescence of multiple samples on a continuous matrix |
| US5763176A (en) * | 1993-07-12 | 1998-06-09 | Slater; James Howard | Methods and devices for marking a solid and subsequently detecting the markings |
| US6506895B2 (en) * | 1997-08-15 | 2003-01-14 | Surmodics, Inc. | Photoactivatable nucleic acids |
| US6383749B2 (en) * | 1999-12-02 | 2002-05-07 | Clontech Laboratories, Inc. | Methods of labeling nucleic acids for use in array based hybridization assays |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020084623A3 (en) * | 2018-10-24 | 2020-07-02 | Apa- Advanced Technologies Ltd. | Fusogenic liposomes for selective imaging of tumor cells |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003528625A (en) | 2003-09-30 |
| WO2001073117A9 (en) | 2002-07-18 |
| AU2001256244A1 (en) | 2001-10-08 |
| WO2001073117A1 (en) | 2001-10-04 |
| EP1268858A1 (en) | 2003-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240392355A1 (en) | In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto | |
| US7927798B2 (en) | Detection of nucleic acids from whole blood | |
| US20050059009A1 (en) | Preparation of nucleic acid samples | |
| US20050003395A1 (en) | Methods and compositions for high throughput identification of protein/nucleic acid binding pairs | |
| EP1880025A2 (en) | Multiplex branched-chain dna assays | |
| JP2020504600A (en) | Improved method for multiplex imaging using labeled nucleic acid imaging agents | |
| JP2008000143A (en) | Bio-barcodes based on oligonucleotide-modified particles | |
| JP2002503948A (en) | Amplification and detection of single molecule segments | |
| JP2007525970A (en) | Target analyte detection based on bio barcode | |
| CA2377567A1 (en) | High throughput assay system | |
| CN108374038B (en) | Method for detecting in vitro a mutated gene, messenger RNA or microRNA in a sample | |
| KR20080094911A (en) | Hybridization Probe Analysis and Arrays | |
| Juul et al. | NanoCluster Beacons as reporter probes in rolling circle enhanced enzyme activity detection | |
| EP3066218B1 (en) | Methods for detecting nucleic acids | |
| CN101001960A (en) | Detection of target analytes based on biological barcodes | |
| EP1431398A1 (en) | A method for detecting in a mixture an amount of analytes | |
| US20030077636A1 (en) | Use of particles which have signal-emitting characteristics and at least one group with an affinity for maked nucleic acids | |
| US6379899B1 (en) | Isothermal exponential RNA amplification in complex mixtures | |
| EP1249503A2 (en) | Multiplexed gene analysis on a mobile solid support | |
| EP1939622B1 (en) | Method of forming autoaggregate on microparticle and method of detecting target analyte | |
| US10982266B2 (en) | Nucleic acid-polymer conjugates for bright fluorescent tags | |
| KR20220069865A (en) | Composition for detecting target nucleic acids, and method for detecting target nucleic acids using the same | |
| JP2003527866A (en) | Methods for detecting polynucleotide kinase and their use as labels | |
| WO2006104979A2 (en) | Method for detecting a target analyte | |
| CN117625748A (en) | A method for detecting single nucleotide polymorphisms in gene sequences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: MEMOREC STOFFEL GMBH MEDIZINISCH-MOLEKULARE ENTWIC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOSIO, ANDREAS;SCHEFFOLD, ALEXANDER;REEL/FRAME:013322/0614 Effective date: 20020731 |
|
| AS | Assignment |
Owner name: MEMOREC BIOTEC GMBH, GERMANY Free format text: RE-RECORD TO CORRECT APPLICATION NUMBER (10/238424) PREVIOUSLY RECORDED AT REEL 14611, FRAME 911;ASSIGNOR:MEMOREC STOFFEL GMBH MEDIZINISCH-MOLEKULARE ENTWICKLUNG KOLN;REEL/FRAME:015097/0069 Effective date: 20030820 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |